The program is designed to provide immunization administration training to hundreds of thousands of pharmacy technicians within weeks.
As coronavirus disease 2019 (COVID-19) vaccine distribution is set to begin in the US, the National Pharmacy Technician Association (NPTA) is launching a nationally-recognized pharmacy technician administered immunization training program.
Developed under the guidance of the US Department of Health and Human Services (HHS), NPTA’s Immunization Administration Training Program is designed to train hundreds of thousands of technicians within weeks, “enabling the rapid deployment of vaccines to the public,” NPTA said in a press release.1
“Unlike the majority of comparable training programs—which typically charge a high fee per technician trained—the NPTA program charges one low, fixed cost per pharmacy to provide the program to an unlimited number of technicians, including new hires, without incurring additional costs,” NPTA said.
The program is designed for both large-scale chains and independent pharmacies.
“The faster we administer vaccines, the more lives we can save,” said Mike Johnston, CPhT, founder and CEO of NPTA. “Pharmacy technicians will be vital to administering COVID-19 vaccines to the public. It’s critical to the public health that we train a large number of technicians in a matter of weeks, so we can efficiently distribute and administer vaccines across the nation.”
References:
As vaccine distribution begins, NPTA launches the nation’s most affordable, accessible & scalable immunization administration training program. News release. NPTA; December 7, 2020. Accessed December 11, 2020. https://www.pharmacytechnician.org/npta/immunizations.asp
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.